Gliknik secures $1.5 million SBIR grant from NCI
BALTIMORE, Md.—Biopharmaceutical company Gliknik Inc. recently announced it had been awarded a Small Business Innovation Research Phase II contract for up to $1.5 million from the National Cancer Institute (NCI). Gliknik develops new therapies for patients suffering from cancer and autoimmune/inflammatory diseases, with a specialty in modulation of the immune system. The company has raised $10 million from investors since being formed in 2007, in large part due to Maryland's biotechnology tax credit, and has attracted $2.5 million in nonequity financing from government sources, including the NCI grant. According to David S. Block, Gliknik's CEO, the grant puts Gliknik on a path that could result in clinical trials in two years. The company will use the contract funds to further advance its leads compounds from its stratobody platform toward the clinic.